Clinical outcomes with lurasidone

Lurasidone is a 2nd generation antipsychotic licensed for the treatment of schizophrenia. In September 2014, the Drugs and Therapeutics Committee approved the use of lurasidone in the trust and all new starters were registered on a pharmacy database. In this evaluation, we aim to follow-up all patients prescribed lurasidone for 1 year to establish what factors influence persistence with treatment and to describe the nature of adverse events observed during the follow-up period. As we already have data on this cohort collected manually by pharmacy staff, a secondary aim of this project is to use that data to validate the results obtained by a tool created by the Bioinformatics group (project no: 13-025 Exploring Adverse Drug Reactions (ADRs) in CRIS using the GATE Text Mining Framework) for extracting data on duration of treatment on a drug. The knowledge gained from this project will help in selecting patients best suited to lurasidone treatment.